Mantle Cell Lymphoma
From the Journals
‘Plethora’ of new MCL treatment options
New and potential treatments have emerged for relapsed/refractory mantle cell lymphoma (R/RMCL), a rare but steadily increasing form of non-...
Feature
Noted oncologist ponders death, life, care inequities
A photojournalist-turned-physician practiced in India and the United Kingdom before rising to prominence in U.S. community oncology.
News
First drug therapy approved for childhood GVHD
FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.
From the Journals
Phase 3 data: Zanubrutinib bests standard CLL treatment
Results could spur FDA approval as frontline therapy.
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.
Conference Coverage
'New benchmark' set in phase-3 blood cancer study
Phase 3 SHINE study of older patients with mantle cell lymphoma yields “profound” results with ibrutinib add-on.
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
Latest News
New trials in lymphoma and MM: Could your patient benefit?
Late-phase clinical trials are opening up, with a chance to enroll one or more of your patients.
Conference Coverage
ZUMA-2, TRANSCEND data pique interest in earlier CAR T for R/R MCL
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...